Resnick Joshua 4
4 · Sionna Therapeutics, Inc. · Filed Jun 16, 2025
Insider Transaction Report
Form 4
Resnick Joshua
Director
Transactions
- Award
Non-Qualified Stock Option (right to buy)
2025-06-12+19,959→ 19,959 totalExercise: $16.99Exp: 2035-06-11→ Common Stock (19,959 underlying)
Footnotes (2)
- [F1]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.
- [F2]This option vests in full upon the earlier of June 12, 2026 or the date of the next annual meeting of Sionna Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date.